Almirall, the Barcelona-based global biopharmaceutical company, reported strong financial results for 2025, achieving double-digit growth across key performance metrics and reinforcing its leadership in medical dermatology.
The company recorded net sales of €1.108 billion, marking a 12.4% increase compared to 2024. Total revenue rose 12.5% to €1.114 billion, while EBITDA grew significantly by 20.9% to €232.9 million, reflecting sustained operational strength and effective commercial execution across its core markets.
Almirall’s European dermatology business remained the primary growth driver, with net sales increasing 25.6% year-on-year to €608 million. The company’s biologics portfolio continued to play a critical role, particularly Ilumetri®, which generated €234.4 million in sales, and Ebglyss®, which recorded rapid growth with sales exceeding €110.8 million in its second year after launch.
Other dermatology products also delivered strong performance. Wynzora® sales increased 30.5% to €33.8 million, while Klisyri® grew 33.9% to €32.8 million, strengthening Almirall’s position as a trusted partner for dermatologists and patients managing chronic skin conditions.
The company’s profitability improved significantly, with net income rising to €46.2 million from €10.1 million in 2024. Normalized net income more than doubled, reflecting improved operational efficiency, strong product demand, and disciplined cost management.
Almirall also maintained strong investment in research and development, allocating €138.1 million, equivalent to 12.5% of net sales, to advance its dermatology pipeline. Key milestones included launching Phase II clinical trials targeting hidradenitis suppurativa and alopecia areata, as well as regulatory approvals for Jublia® in Germany and Seysara® in China.
The company ended 2025 with a strong financial position, reporting zero net debt relative to EBITDA and generating €174.5 million in operating cash flow. Gross margin remained stable at 64.4%, supporting continued reinvestment in innovation and expansion.
Looking ahead, Almirall expects continued growth in 2026, projecting net sales growth of 9% to 12% and EBITDA between €270 million and €290 million. The company aims to further expand its biologics portfolio and advance its research pipeline to address unmet medical needs in dermatology.
Almirall’s leadership emphasized that strong commercial performance, expanding biologics adoption, and continued innovation will support its long-term growth strategy and strengthen its impact on patients living with skin diseases worldwide.